Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Company Profile Canoe EIT Income 4.80 Cumulative Redeemable Pref shs Series 1 T.EIT.PR.A

Alternate Symbol(s):  T.EIT.PR.B | ENDTF | T.EIT.UN

Financial Services Asset Management
Canoe EIT Income Fund is a Canadian closed-end investment trust. The investment objective of the Fund is to maximize monthly distributions relative to risk and maximize net asset value while maintaining and expanding a diversified portfolio. The company invests in various sectors, of which Financials, Energy, Healthcare, etc.

Showcase News Releases

Showcase news

Nextech3D.ai
Nextech3D.ai Sees Ecommerce Industry Shift Accelerating to 3D Models As Major Ecommerce Platforms Discontinue 360 Spin Experiences In Favor of 3D-AI and Augmented Reality (AR) Technologies
Hank Payments Corp.
Hank Payments Auto Channel Continues Accelerated Growth
Theralase Technologies Inc.
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically

More Showcase News Releases »